This study was performed to evaluate the antifungal activities of methanolic fractions from the stem bark of Entada spiralis Ridl. against human dermatophytes and yeast-like fungus in vitro. Three types of human dermatophyte, Trichophyton mentagrophytes ATCC 9533, Microsporum gypseum ATCC 24102 and Trichophyton tonsurans ATCC 28942, and one yeast-like fungus, Candida glabrata ATCC 66032, were tested against the methanolic fractions labelled FA1, FA4 and FA5. T. mentagrophytes, T. tonsuran and M. gypseum were susceptible to all tested fractions in a concentration-dependent manner whereas C. glabrata was resistant. Fraction FA1 at a concentration of 400 mg/mL was found to exhibit the highest antifungal activity with the inhibition zone diameter of 22 mm (T. mentagrophytes). This fraction showed a minimum inhibitory concentration MIC of 0.097 mg/mL while the MIC value for the fraction FA4 and fraction FA5 was 3.12 mg/ml and 1.56 mg/ml respectively. Agar overlay bioautography assay results showed that most of the bioactive compounds were found in the fraction FA1. Based on these findings, it can be concluded that the stem bark extracts of E. spiralis can be a future source of potent natural antimicrobial drugs for superficial skin diseases.
The present study was designed to compare the antibacterial effect between stem and leaves of Entada spiralis against soft rot bacteria Erwinia chrysanthemi and its antioxidant properties which could benefit to indigenous people. E. spiralis which locally knows as ‘sintok’ is a liana and it grows wildly in Malaysia. Indigenous people are utilizing this plant as natural washing agent and shampoo as well as ethnomedicine to cure diseases since they have little access to modern medicines. E. chrysanthemi is bacteria which commonly cause soft-rot disease of vegetables. The antibacterial activity of stem and leaves of E. spiralis against E. chrysanthemi were evaluated from disc diffusion method. The DPPH radical scavenging method and dot blot assay were utilized to see the potential of stem and leaves of E. spiralis as an antioxidant agent. The results indicated that the leaves part was more antioxidative than stem of E. spiralis with IC50 of 10.5 μg/mL. Ethyl acetate extract from stem part at concentration of 200 mg/mL was found to be the most active extract against E. chrysanthemi with the highest inhibition zone of 16.3mm. The investigation is hoped to provide basic information for the development of potent natural pesticides and natural remedy which is safer and eco-friendly.
As the Malaysian population ages, the burden of age-related cognitive disorders such as dementia and Alzheimer’s disease will increase concomitantly. This is one of the sub-study under a research project titled by quantify the cost of age-related cognitive impairment in Malaysia, which was undertaken to develop a clinical pathway for Mild Cognitive Impairment (MCI) and Dementia. The clinical pathway (CP) will be used to support the costing studies of MCI and Dementia. An expert group discussion (EGD) was conducted among selected experts from six (6) government hospitals from different states of Malaysia, Ministry of Health, and United Nations University, International Institute for Global Health, UKM and UPM. The expert group includes psychiatrist specialists and public health medicine specialists. A total of 15 participants took part in the EGD. The group was presented with the different approach in managing MCI and Dementia. Finally, the group came to the consensus agreement on the most appropriate and efficient ways of managing the two conditions. In the EGD, an operational definition for MCI and Dementia was agreed upon and a pathway was developed for the usual practice in the Malaysian health system. A typical case used, as a reference is a 60-year-old patient referred to a memory clinic with complaint of “forgetfulness”. After three outpatient visits in the clinic, the diagnosis of MCI and Dementia could be clinically established. The clinical pathways covered all active clinical and non-clinical management of the patient over a period of one year. The experts identified the additional resources required to manage these patients for the whole spectrum of lifetime based on the expected life expectancy. The Clinical pathway (CP) for MCI and Dementia was successfully developed in EGD with strong support from practitioners in the health system. The findings will help the researchers to identify all-important clinical activities and interventions that will be included in the costing study.